TrialThe Journal of allergy and clinical immunology2021

Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.

Kathleen M Buchheit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.